Association Between Medicaid Expansion and Insurance Status, Risk Group, Receipt, and Refusal of Treatment Among Men with Prostate Cancer

Cancers, Journal Year: 2025, Volume and Issue: 17(3), P. 547 - 547

Published: Feb. 6, 2025

Background: Although the Patient Protection and Affordable Care Act (ACA) has been associated with increased Medicaid coverage among prostate cancer patients, association between expansion risk group at diagnosis, time to treatment initiation (TTI), refusal of locoregional (LT) patients requires further exploration. Methods: Using National Cancer Database, we performed a retrospective cohort analysis all aged 40 64 years diagnosed localized from 2011 2016. Difference-in-difference (DID) was used compare changes in insurance status, TTI, LT residing versus non-expansion states. In secondary analysis, DID above outcomes racial minorities White living Results: Of 112,434 our 50,958 lived states, 61,476 adjusted found that proportion uninsured (adjusted DID: −0.87%; 95% confidence interval [95% CI]: −1.28 −0.46) who refused radiation therapy −0.71%; CI: −0.95 −0.47) decreased more states compared Similarly, observed disparity select narrowed, as experienced larger absolute decreases status (RT) regimens than following ACA implementation (p < 0.01 for all). However, residence state not nor > all); disparities TTI were also exacerbated implementation. Conclusions: The remains unclear. While RT, there no significant earlier within 180 days, or LT. had RT regimens, well smaller increases intermediate-/high-risk disease presentation implementation, but TTI. More research is needed understand how affects whether these effects are borne equitably different populations.

Language: Английский

---

Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status quo and outlook

The EPMA Journal, Journal Year: 2023, Volume and Issue: 14(1), P. 143 - 165

Published: Jan. 25, 2023

Abstract A form of genomic alteration called microsatellite instability (MSI) occurs in a class tandem repeats (TRs) microsatellites (MSs) or short (STRs) due to the failure post-replicative DNA mismatch repair (MMR) system. Traditionally, strategies for determining MSI events have been low-throughput procedures that typically require assessment tumours as well healthy samples. On other hand, recent large-scale pan-tumour studies consistently highlighted potential massively parallel sequencing (MPS) on scale. As result innovations, minimally invasive methods show high be integrated into clinical routine and delivery adapted medical care all patients. Along with advances technologies their ever-increasing cost-effectiveness, they may bring about new era Predictive, Preventive Personalised Medicine (3PM). In this paper, we offered comprehensive analysis high-throughput computational tools calling events, including whole-genome, whole-exome targeted approaches. We also discussed detail detection status by current MPS blood-based hypothesised how contribute shift from conventional medicine predictive diagnosis, prevention personalised services. Increasing efficacy patient stratification based is crucial tailored decision-making. Contextually, paper highlights drawbacks both at technical level those embedded deeper cellular/molecular processes future applications testing.

Language: Английский

---

Inflammation-related indicators have a potential to increase overall quality of the prostate cancer management: a narrative review

Translational Andrology and Urology, Journal Year: 2023, Volume and Issue: 12(5), P. 809 - 822

Published: May 1, 2023

Background and Objective: Increasing evidence suggests that inflammation plays an essential role in cancer development progression. The levels of inflammation-related indicators are correlated with prognosis across a wide variety tumor types, including prostate (PCa), but its diagnostic prognostic value PCa remains controversial. In the present review, patients is investigated.

Language: Английский

---

FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma

Journal of Translational Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Jan. 17, 2023

Pancreatic ductal adenocarcinoma (PDAC) and prostate cancer (PCa) are among the most prevalent malignant tumors worldwide. There is now a comprehensive understanding of metabolic reprogramming as hallmark cancer. Fatty acid synthase (FASN) key regulator lipid network, providing energy to favor tumor proliferation development. Whereas biological role FASN known, its response sensitivity inhibition have not yet been fully established in these two settings.To evaluate association between expression, methylation, prognosis, mutational profile PDAC PCa, we interrogated public databases surveyed online platforms using TCGA data. The STRING database was used investigate interactors, Gene Set Enrichment Analysis platform Reactome perform an enrichment analysis data from RNA sequencing PCa. In vitro models PCa cell lines were corroborate expression FASN, shown by Western blot, effects on proliferation/cell cycle progression mitochondrial respiration investigated with MTT, colony formation assay, MitoStress Test.The modulated compared normal pancreatic tissues, while it overexpressed which also displayed different level promoter methylation. Based grade, decreased advanced stages PDAC, but increased A low incidence mutations found for both tumors. despite reaching statistical significance, associated worse prognosis than PDAC. interactors correlated metabolism, GSEA indicated that lipid-mediated enriched Following validation overexpression vitro, tested TVB-2640 inhibitor. arrest dose- time-dependent manner, whereas altered. line this finding, be more affected interfered signaling causing accumulation affecting viability impact replicative processes.FASN exhibited differential patterns suggesting evolution during progression. This corroborated fact responded differently terms proliferative potential respiration, indicating use should reflect context specificity.

Language: Английский

---

Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States

Journal of Medical Economics, Journal Year: 2024, Volume and Issue: 27(1), P. 381 - 391

Published: Feb. 29, 2024

Aims: To describe healthcare resource utilization (HRU) and costs of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Language: Английский

---

Unveiling the latest insights into Androgen Receptors in Prostate Cancer

International journal of medical biochemistry/International journal of medical biochemistry :, Journal Year: 2024, Volume and Issue: unknown, P. 101 - 113

Published: Jan. 1, 2024

C ancer, characterized by uncontrolled cell growth, remains a significant concern worldwide [1].Prostate cancer (PCa) specifically targets the walnut-shaped prostate gland in male reproductive system [2].It stands as one of most commonly diagnosed cancers among men and leading cause global cancer-related deaths [3].The incidence PCa has surged recent years, with an estimated increase 1 every 52 males aged 50 to 59 [4,5].1.4 million new cases were documented 2020 [6].Incidence rates for vary different populations regions.Men from Europe, Latin Prostate is major mortality worldwide, rising observed over years.The androgen receptor (AR) signaling pathway plays pivotal role development maintaining masculine characteristics.Dysregulation AR can lead disease progression resistance standard therapies.Understanding intricate regulation function both healthy diseased states crucial developing effective treatment strategies.This review comprehensively explores receptors susceptibility, progression, response analyzing literature.An extensive search peer-reviewed publications databases, including PubMed, Scopus, Web Science, was conducted using specific keywords related receptor, cancer, resistance.Relevant conference abstracts clinical trial reports also included.The presents overview initiation, resistance.It highlights SPOP emerging biomarker associated dysregulation their potential utility early detection personalized approaches.Additionally, advances targeting novel therapeutic strategies improve patient outcomes overcome advanced are discussed.The findings contribute comprehensive understanding offer insights into its multifaceted response.They may pave way innovative interventions precision medicine approaches based on profiles, enhancing care reducing burden this lethal disease.

Language: Английский

---

MiR-375 and miR-21 as Potential Biomarkers of Prostate Cancer: Comparison of Matching Samples of Plasma and Exosomes

Genes, Journal Year: 2022, Volume and Issue: 13(12), P. 2320 - 2320

Published: Dec. 9, 2022

MiR-21 and miR-375 have been reported as dysregulated in prostate cancer (PCa) multiple previous studies. Still, variable or even opposing data for the expression of these microRNAs PCa were found, their potential biomarker properties remain elusive. In an attempt to clarify significance biomarkers, well compare different types specimens a source relevant microRNAs, we used plasma matching plasma-derived exosomes from patients with benign prostatic hyperplasia (BPH). Plasma obtained 34 BPH, levels miR-21 determined by RT-qPCR. We found no significant difference level between BPH. The exosomal was elevated high serum PSA values, aggressive PCa, while samples, results remained insignificant. For miR-375, did not find association values standard prognostic parameters nor aggressiveness. Therefore, our support role PCa.

Language: Английский

---

The association between sexual dysfunction and prostate cancer: a systematic review and meta-analysis

The Journal of Sexual Medicine, Journal Year: 2023, Volume and Issue: 20(2), P. 184 - 193

Published: Jan. 16, 2023

Language: Английский

---

Improving Whole Tomato Transformation for Prostate Health: Benign Prostate Hypertrophy as an Exploratory Model

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(6), P. 5795 - 5795

Published: March 17, 2023

It is well-established that the beneficial properties of single phytonutrients can be better attained when they are taken with complex molecules present in their natural milieu. Tomato, fruit providing most comprehensive prostate-health-preserving micronutrients, has been shown to superior its single-nutrient counterparts decreasing incidence age-related prostate diseases. Herein, we describe a novel tomato food supplement enriched olive polyphenols, containing cis-lycopene concentrations far exceeding those industry-produced commodities. The supplement, endowed antioxidant activity comparable N-acetylcysteine, significantly reduced, experimental animals, blood levels prostate-cancer-promoting cytokines. In prospective, randomized, double-blinded, placebo-controlled studies performed on patients affected by benign prostatic hyperplasia, uptake improved urinary symptoms and quality life. Therefore, this complement and, some cases, an alternative current hyperplasia management. Furthermore, product suppressed carcinogenesis TRAMP mouse model human cancer interfered molecular signaling. Thus, it may offer step forward exploring potential consumption delay or prevent onset diseases high-risk individuals.

Language: Английский

---

Amygdalin Exerts Antitumor Activity in Taxane-Resistant Prostate Cancer Cells

Cancers, Journal Year: 2022, Volume and Issue: 14(13), P. 3111 - 3111

Published: June 24, 2022

Despite recent advances in the treatment of metastatic prostate cancer (PCa), resistance development after taxane treatments is inevitable, necessitating effective options to combat drug resistance. Previous studies indicated antitumoral properties natural compound amygdalin. However, whether amygdalin acts on drug-resistant tumor cells remains questionable. An vitro study was performed investigate influence (10 mg/mL) growth a panel therapy-naïve and docetaxel- or cabazitaxel-resistant PCa cell lines (PC3, DU145, LNCaP cells). Tumor growth, proliferation, clonal cycle progression were investigated. The regulating proteins (phospho)cdk1, (phospho)cdk2, cyclin A, B, p21, p27 mammalian target rapamycin (mTOR) pathway (phospho)Akt, (phospho)Raptor, (phospho)Rictor as well integrin β1 cytoskeletal vimentin, ezrin, talin, cytokeratin 8/18 assessed. Furthermore, chemotactic activity adhesion extracellular matrix components analyzed. Amygdalin dose-dependently inhibited reduced clones all (parental resistant) lines, accompanied by G0/G1 phase accumulation. Cell significantly altered A moderate chemotaxis observed well, paralleled modifications expression level. may, therefore, block disseminative characteristics taxane-resistant cells. Further are warranted determine amygdalin's value an antitumor drug.

Language: Английский

---